Cargando…

Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis

BACKGROUND: Breast cancer is one of the most common cancers in the world, and the identification of biomarkers for the early detection of breast cancer is a relevant target. The present study aims to determine serum peptidome patterns for screening of breast cancer. METHODS: The present work focused...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Nai-Jun, Gao, Chun-Fang, Zhao, Guang, Wang, Xiu-Li, Liu, Qing-Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584670/
https://www.ncbi.nlm.nih.gov/pubmed/22521044
http://dx.doi.org/10.1186/1746-1596-7-45
Descripción
Sumario:BACKGROUND: Breast cancer is one of the most common cancers in the world, and the identification of biomarkers for the early detection of breast cancer is a relevant target. The present study aims to determine serum peptidome patterns for screening of breast cancer. METHODS: The present work focused on the serum proteomic analysis of 36 healthy volunteers and 37 breast cancer patients using a ClinProt Kit combined with mass spectrometry (MS). This approach allows the determination of peptidome patterns that are able to differentiate the studied populations. An independent group of sera (36 healthy volunteers and 37 breast cancer patients) was used to verify the diagnostic capabilities of the peptidome patterns blindly. An immunoassay method was used to determine the serum mucin 1 (CA15-3) of validation group samples. RESULTS: Support Vector Machine (SVM) Algorithm was used to construct the peptidome patterns for the identification of breast cancer from the healthy volunteers. Three of the identified peaks at m/z 698, 720 and 1866 were used to construct the peptidome patterns with 91.78% accuracy. Furthermore, the peptidome patterns could differentiate the validation group achieving a sensitivity of 91.89% (34/37) and a specitivity of 91.67% (33/36) (> CA 15–3, P < 0.05). CONCLUSIONS: These results suggest that the ClinProt Kit combined with MS shows great potentiality for the diagnosis of breast cancer. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1501556838687844